Making more precise cancer-targeting medicines using special amino acids
Bioconjugations Employing Unnatural Amino Acids
Researchers are using uncommon amino acids to build precise antibody-linked drug-and-tracer combinations that could help deliver cancer medicines more accurately and let doctors see where they go.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | College of William and Mary NIH-funded |
| Lab location | 1 site (Williamsburg, United States) |
| Project ID | NIH-11220470 on NIH RePORTER |
What this research studies
From my point of view as a patient, the team is adding special, nonstandard amino acids into proteins so those proteins have exact attachment points. They are developing gentle chemical reactions that work in water and at body-like conditions to link drugs, antibodies, and tracking dyes. The researchers plan to combine these steps to make multivalent conjugates that can carry a targeting antibody, a small‑molecule cancer drug, and a fluorescent tag in one well-defined molecule. Most of this work happens in the lab to optimize chemistry and the activity of the conjugates before any patient testing.
Who could benefit from this research
Good fit: This work is most relevant to people with cancers that are or could be treated with antibody‑drug conjugates, though the project itself is preclinical lab research rather than a patient trial.
Not a fit: Patients without cancer or those seeking immediate clinical treatment are unlikely to benefit directly from this laboratory-focused project.
Why it matters
Potential benefit: If successful, this could produce antibody-drug conjugates that deliver cancer drugs more precisely, lower side effects, and allow tracking of drug delivery.
How similar studies have performed: Antibody-drug conjugates are already an approved approach in cancer care, but using noncanonical amino acids and the described new bioconjugation chemistries is a relatively new and less-tested method.
Where this research is happening
Williamsburg, United States
- College of William and Mary — Williamsburg, United States (Active)
Researchers
- Principal investigator: Young, Douglas — College of William and Mary
- Study coordinator: Young, Douglas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.